PsyPost
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Neuroscience
  • About
No Result
View All Result
Join
My Account
PsyPost
No Result
View All Result
Home Exclusive Mental Health Anxiety

Popular weight loss and diabetes drugs show no biological link to mental illness

by Karina Petrova
June 6, 2026
Reading Time: 4 mins read
[Adobe Stock]

[Adobe Stock]

Medications used to treat diabetes and obesity do not appear to increase the risk of mental health conditions like depression, anxiety, or suicide. A new study combining genetic analysis and real-world clinical data found no evidence tying glucagon-like peptide-1 receptor agonists to psychiatric disorders. The findings were published in the Journal of Affective Disorders.

Glucagon-like peptide-1 is a naturally occurring hormone produced in the intestines. When a person eats, this hormone prompts the pancreas to release insulin to manage blood sugar levels. It also sends signals to the brain to promote a feeling of fullness. Pharmaceutical companies developed synthetic versions of this hormone to help patients manage type 2 diabetes.

These medications are known as glucagon-like peptide-1 receptor agonists. Because they effectively slow digestion and reduce appetite, they have recently gained immense popularity as weight loss treatments. However, as millions of people began taking these drugs, health authorities started receiving troubling reports.

Patients and doctors submitted accounts to the European Medicines Agency and the United States Food and Drug Administration detailing adverse psychiatric events. Some individuals reported experiencing intense anxiety, new depressive symptoms, or suicidal thoughts after starting the injections. Because the drugs interact with brain regions involved in reward and emotional regulation, medical professionals worried about potential psychiatric side effects.

Investigating these reports using standard observational data has proven exceptionally difficult. Patients prescribed these medications usually have chronic conditions like diabetes or clinical obesity. These underlying health issues are already associated with a higher baseline risk for depression and anxiety, making it hard to separate the effects of the disease from the effects of the drug.

Additionally, rapid weight loss itself can cause immense psychological shifts. Some early studies suggested the medications might trigger mental health issues, while other reviews found they actually reduced suicidal ideation compared to alternative treatments. To bypass the limitations of observational research, Chenhao Ouyang, a researcher at Nanchang University in China, and colleagues designed an alternative approach.

The team utilized an epidemiological technique called Mendelian randomization. This method relies on the fact that genetic variations are passed down randomly from parents to children at conception. Because this genetic lottery is unaffected by lifestyle choices or environmental factors, scientists can use it as a natural experiment to help establish cause and effect.

The researchers searched massive genetic databases for specific DNA variations that naturally alter how the body’s glucagon-like peptide-1 receptors function. These genetic tweaks serve as a lifelong proxy for taking the medication. If the biological pathway activated by the weight loss drugs genuinely causes mental health problems, people carrying these specific genetic variations should exhibit higher rates of mental illness.

To conduct the Mendelian randomization analysis, the researchers needed highly specific genetic data. They utilized two layers of biological information to create their genetic proxies. First, they looked at variations altering gene expression, which dictates how actively the body reads the DNA code to produce the receptor. Second, they examined variations affecting the actual abundance of the receptor protein circulating in the body. Finding consistent results across both biological variables helps verify the reliability of the overall conclusions.

The team accessed data from massive international genetics initiatives, including the FinnGen project and the Psychiatric Genomics Consortium. FinnGen alone contains biological samples and health records from over half a million Finnish citizens. The Psychiatric Genomics Consortium involves hundreds of researchers globally and features data from hundreds of thousands of participants, ensuring a robust sample size for detecting rare conditions.

Using these databases, the researchers compared the genetic proxies for receptor activity against the genetic profiles of seven distinct psychiatric conditions. The targeted disorders included anxiety, bipolar affective disorder, chronic depression, major depression, eating disorders, suicide, and schizophrenia.

Applying several statistical models, the investigators looked for overlapping patterns. They tested whether the genes dictating receptor activity and the genes associated with mental illness were inherited together. They also checked for shared genetic architecture across the different traits.

The genetic results showed no connection at all between the biological target of the drugs and the psychiatric conditions. Natural variations in the receptor did not alter a person’s risk for any of the seven mental health disorders. The researchers found no shared causal variants driving both the receptor’s function and the occurrence of mental illness.

To test these genetic findings against physical practice, Ouyang and the research team also conducted a wide-ranging review of existing clinical data. They performed a meta-analysis, which is a statistical process that combines the results of multiple independent studies to identify broader trends. They gathered thirty-five prior studies that documented real-world mental health outcomes in patients.

This pooled data compared individuals taking the medications to control groups receiving alternative treatments or placebos. The clinical review mirrored the genetic analysis perfectly. Patients taking the weight loss and diabetes medications did not have a statistically significant difference in rates of anxiety, depressive symptoms, or suicidal behavior.

The researchers did find one exception in the clinical data, specifically regarding eating disorders. Patients using the medications showed noticeable improvements in eating disorder symptoms compared to those not taking the drugs. The authors suggest this could occur because the medications influence the brain’s reward centers to reduce the frequency and severity of binge eating behaviors.

Despite the reassuring results, the investigators noted several limitations to their work. Their analysis of the clinical data did not separate patients who had a prior history of mental illness from those without such a background. Making this distinction in future studies might help researchers better understand why isolated reports of depression or suicide still occur in some patients.

The genetic data utilized in the study predominantly came from individuals of European descent. This focus means the results might not perfectly translate to other global populations with different genetic backgrounds. The project also did not look at how varying medication doses might influence psychological health over extended periods.

The available genetic data for the receptor was somewhat sparse, which can sometimes lead to unstable statistical estimates. The authors recommend future prospective clinical trials to track mental health outcomes over time in diverse populations. They specifically highlight the need for research focusing on subgroups like patients with pre-existing binge eating disorders to verify the potential benefits observed in this review.

Overall, the combined genetic and real-world results offer theoretical support for the psychological safety of these widely used treatments. The biological mechanisms that make the drugs effective for metabolic conditions do not appear to inherently drive psychiatric distress.

The study, “Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence,” was authored by Chenhao Ouyang, Xiaoyue Zhang, Minhai Zhang, Yan Miao, Zicheng Zhu, Yunting Zeng, Hong Ban, Yuting Wu, Nanqin Peng, Jitao Ling, Chen Li, Deju Zhang, Peng Yu, Jing Zhang, Xiao Liu, and Tongsheng Huang.

TweetSendScanShareSendPin9ShareShareShareShareShare

Follow PsyPost

The latest research, however you prefer to read it.

Daily newsletter

One email a day. The newest research, nothing else.

Google News

Get PsyPost stories in your Google News feed.

Add PsyPost to Google News
RSS feed

Use your favorite reader.

Copy RSS URL
Social media
Support independent science journalism

Ad-free reading, full archives, and weekly deep dives for members.

Become a member

Trending

  • Women want to talk about sex with their close friends more often, study finds
  • Scientists uncover how a tiny reflection of light helps us navigate the social world
  • Over 10 percent of factual claims in Google’s AI search summaries aren’t backed by their cited sources, study finds
  • Inflammation briefly dampens pleasure and the desire to socialize, placebo-controlled study finds
  • Narcissistic parents tend to lean on their children for emotional support, and that is linked to depression later on

Science of Money

  • For male startup founders, average looks may pay off best in the pitch room, according to new Shark Tank study
  • Why struggling with bills feels even worse when you think the economy is booming
  • Feeling stuck in an unwanted work location takes a measurable toll on mental health
  • Why having a self-sacrificing boss can feel like a trap, according to psychology
  • News about shortages only triggers stockpiling when shoppers start searching online, study finds

Recent

  • Loving-kindness meditation fails to beat muscle relaxation for pain or social well-being in online trial
  • Losing childhood weight by adulthood might erase later depression risks
  • Women don’t find deeper-than-average voices more attractive when they can see the man
  • Voters value long-term economic growth more than previously thought, study finds
  • Scientists map a blood protein fingerprint of menopause tied to brain health
  • Social anxiety might not warp how we perceive eye contact
  • In female mice modeling schizophrenia, a single dose of psilocybin restored sensory filtering for days
  • Could psychedelics aid therapy for personality disorders? An unusual case offers a first look
  • Schizophrenia is linked to broad difficulty reading emotions from body language and faces
  • Socially isolated and lonely people tend to be biologically older than their years

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Mental Health
  • Neuroimaging
  • Personality Psychology
  • Social Psychology
  • Artificial Intelligence
  • Cognitive Science
  • Psychopharmacology
  • Contact us
  • Disclaimer
  • Privacy policy
  • Terms and conditions
  • FAQ

(c) PsyPost Media Inc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

(c) PsyPost Media Inc